• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down 1.10% Nasdaq Down 1.82%

    Alnylam Pharmaceuticals, Inc. (ALNY)

    -NasdaqGS
    60.61 Down 4.98(7.59%) 4:00PM EST
    |After Hours : 59.42 Down 1.19 (1.96%) 6:04PM EST
    Prev Close:65.59
    Open:64.14
    Bid:54.25 x 100
    Ask:118.00 x 200
    1y Target Est:144.42
    Beta:2.25271
    Next Earnings Date:11-Feb-16ALNY Earnings announcement
    Day's Range:59.42 - 64.93
    52wk Range:59.42 - 140.00
    Volume:1,175,571
    Avg Vol (3m):889,026
    Market Cap:5.14B
    P/E (ttm):N/A
    EPS (ttm):-2.69
    Div & Yield:N/A (N/A)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Headlines

    » More Headlines for ALNY

    Comparison

    Symbol% ChgMkt Cap
    ALNYDown 7.59%5.14B
    PFEDown 1.62%176.32B
    MRKDown 1.11%136.41B

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):96.55
    Ex-Dividend Date:N/A

    Analysts

    Annual EPS Est (Dec-15) :-3.31
    Quarterly EPS Est (Dec-15) :-0.96
    Mean Recommendation*:1.9
    PEG Ratio (5 yr expected):-0.43

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase ... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback